Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHB937 single ascending dose study in healthy Japanese adults
jRCT2071240007Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing VHB937 single-dose intravenous arm with Placebo single-dose intravenous arm (2 arms). Primary endpoints: Treatment-emergent adverse events, Vital signs and 5 more. Started Apr 2024; status: completed.
02
Drugs
VHB937
Beyond the preview
Go deeper on jRCT2071240007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240007.